Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant born at gestational age less than 34 weeks~* Birth weight less than 2500 grams~* Diagnosis of stage II or III NEC made by attending neonatologist, neonatology fellow, or pediatric hospitalist~* Legally authorized representative is able to provide written informed consent prior to the performance of an protocol-specified evaluations or procedures~* Consent can be obtained and study drug can be administered within 6 hours of diagnosis~Exclusion Criteria:~* congenital gastrointestinal anomaly~* subject is already receiving parenteral steroid therapy or subject has received parenteral steroids within one week prior to study entry~* subject has received indomethacin therapy within 48 hours prior to being diagnosed with NEC

- Gender: ALL
- Minimum Age: 0 Days
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- hydrocortisone (Type: EXPERIMENTAL): Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.

Based on this trial design, predict the completion outcome and termination type (if applicable).